1529 related articles for article (PubMed ID: 29018174)
21. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
22. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
Docherty KF; McMurray JJV; Claggett BL; Miao ZM; Adams KF; Arias-Mendoza A; Cleland JGF; Diaz R; Echeverria Correa LE; Felker GM; Fonseca C; Li J; Metra M; Sliwa-Hahnle K; Solomon SD; Vandekerckhove HJ; Vinereanu D; Voors AA; Heitner SB; Kupfer S; Malik FI; Meng L; Teerlink JR
Eur J Heart Fail; 2023 Feb; 25(2):248-259. PubMed ID: 36597719
[TBL] [Abstract][Full Text] [Related]
24. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
25. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
[TBL] [Abstract][Full Text] [Related]
26. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.
Parcha V; Patel N; Kalra R; Suri SS; Arora G; Wang TJ; Arora P
J Am Heart Assoc; 2021 Apr; 10(7):e018689. PubMed ID: 33754794
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
28. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
30. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
32. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
33. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
34. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
[TBL] [Abstract][Full Text] [Related]
35. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
Kuronuma K; Okumura Y; Morikawa T; Yokoyama K; Matsumoto N; Tachibana E; Oiwa K; Matsumoto M; Kojima T; Haruta H; Nomoto K; Sonoda K; Arima K; Kogawa R; Takahashi F; Kotani T; Ohkubo K; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Int Heart J; 2020 May; 61(3):492-502. PubMed ID: 32418966
[TBL] [Abstract][Full Text] [Related]
37. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
38. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.
Werhahn SM; Becker C; Mende M; Haarmann H; Nolte K; Laufs U; Zeynalova S; Löffler M; Dagres N; Husser D; Dörr M; Gross S; Felix SB; Petersmann A; Herrmann-Lingen C; Binder L; Scherer M; Hasenfuß G; Pieske B; Edelmann F; Wachter R
ESC Heart Fail; 2022 Feb; 9(1):100-109. PubMed ID: 34850596
[TBL] [Abstract][Full Text] [Related]
39. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
40. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]